Drug Transporter Gene Expression in Human Colorectal Tissue and Cell Lines

Modulation with Antiretrovirals for Microbicide Optimization

Indrani Mukhopadhya, Graeme I. Murray, Susan Berry, John Thomson, Bruce Frank, Garry Gwozdz, Julia Ekeruche-Makinde, Robin Shattock, Charles Kelly, Francesco Iannelli, Gianni Pozzi, Emad M. El-Omar, Georgina L. Hold, Karolin Hijazi

Research output: Contribution to journalArticle

5 Citations (Scopus)
4 Downloads (Pure)

Abstract

Objectives To comprehensively assess mRNA expression of 84 drug transporters in human colorectal biopsies and 6 representative cell lines. To investigate the alteration of drug transporter gene expression after exposure to three candidate microbicidal ARV drugs, (tenofovir, darunavir and dapivirine) in Caco-2 cells. The outcome of the objectives informs development of optimal antiretroviral (ARV)-based microbicidal formulations for prevention of HIV-1 infection.
Methods Drug transporter mRNA expression was quantified from colorectal biopsies and cell-lines by quantitative real-time PCR. Relative mRNA expression was quantified in Caco-2 cells after induction with ARVs. Data was analysed using Pearson’s correlation coefficients (r), hierarchical clustering and principal component analysis (PCA).
Results Expression of 58 of the 84 transporters was documented in colorectal biopsies, with CNT2, P-gp and MRP3 being the highest expressed. No difference was noted between individual subjects, when analysed by age, gender or biopsy site (rectum or recto-sigmoid) (r=0.95-0.99). High expression of P-gp and CNT2 proteins was confirmed by immunohistochemical staining. Similarity between colorectal tissue and cell-line drug transporter gene expression was variable (r = 0.64-0.84). PCA showed distinct clustering of human colorectal biopsy samples with the Caco-2 cells defined as the best surrogate system. Induction of Caco-2 cell-lines with ARV drugs suggests that darunavir-based microbicides incorporating tenofovir may result in drug-drug interactions likely to affect distribution of individual drugs to sub-epithelial target cells.
Conclusions These findings will help optimise complex formulations of rectal microbicides to realise their full potential as an effective approach for pre-exposure prophylaxis against HIV-1 infection.
Original languageEnglish
Pages (from-to)372-386
Number of pages15
JournalJournal of Antimicrobial Chemotherapy
Volume71
Issue number2
Early online date29 Oct 2015
DOIs
Publication statusPublished - Feb 2016

Fingerprint

Anti-Infective Agents
Gene Expression
Cell Line
Caco-2 Cells
Tenofovir
Pharmaceutical Preparations
Biopsy
Principal Component Analysis
Messenger RNA
HIV Infections
Cluster Analysis
HIV-1
Sigmoid Colon
Drug Interactions
Rectum
Real-Time Polymerase Chain Reaction
Epithelial Cells
Staining and Labeling

Cite this

Drug Transporter Gene Expression in Human Colorectal Tissue and Cell Lines : Modulation with Antiretrovirals for Microbicide Optimization. / Mukhopadhya, Indrani; Murray, Graeme I.; Berry, Susan; Thomson, John; Frank, Bruce ; Gwozdz, Garry; Ekeruche-Makinde, Julia ; Shattock, Robin; Kelly, Charles; Iannelli, Francesco ; Pozzi, Gianni; El-Omar, Emad M.; Hold, Georgina L.; Hijazi, Karolin.

In: Journal of Antimicrobial Chemotherapy, Vol. 71, No. 2, 02.2016, p. 372-386.

Research output: Contribution to journalArticle

Mukhopadhya, Indrani ; Murray, Graeme I. ; Berry, Susan ; Thomson, John ; Frank, Bruce ; Gwozdz, Garry ; Ekeruche-Makinde, Julia ; Shattock, Robin ; Kelly, Charles ; Iannelli, Francesco ; Pozzi, Gianni ; El-Omar, Emad M. ; Hold, Georgina L. ; Hijazi, Karolin. / Drug Transporter Gene Expression in Human Colorectal Tissue and Cell Lines : Modulation with Antiretrovirals for Microbicide Optimization. In: Journal of Antimicrobial Chemotherapy. 2016 ; Vol. 71, No. 2. pp. 372-386.
@article{39af91393e2b457b9254f2836d7b5a7b,
title = "Drug Transporter Gene Expression in Human Colorectal Tissue and Cell Lines: Modulation with Antiretrovirals for Microbicide Optimization",
abstract = "Objectives To comprehensively assess mRNA expression of 84 drug transporters in human colorectal biopsies and 6 representative cell lines. To investigate the alteration of drug transporter gene expression after exposure to three candidate microbicidal ARV drugs, (tenofovir, darunavir and dapivirine) in Caco-2 cells. The outcome of the objectives informs development of optimal antiretroviral (ARV)-based microbicidal formulations for prevention of HIV-1 infection.Methods Drug transporter mRNA expression was quantified from colorectal biopsies and cell-lines by quantitative real-time PCR. Relative mRNA expression was quantified in Caco-2 cells after induction with ARVs. Data was analysed using Pearson’s correlation coefficients (r), hierarchical clustering and principal component analysis (PCA).Results Expression of 58 of the 84 transporters was documented in colorectal biopsies, with CNT2, P-gp and MRP3 being the highest expressed. No difference was noted between individual subjects, when analysed by age, gender or biopsy site (rectum or recto-sigmoid) (r=0.95-0.99). High expression of P-gp and CNT2 proteins was confirmed by immunohistochemical staining. Similarity between colorectal tissue and cell-line drug transporter gene expression was variable (r = 0.64-0.84). PCA showed distinct clustering of human colorectal biopsy samples with the Caco-2 cells defined as the best surrogate system. Induction of Caco-2 cell-lines with ARV drugs suggests that darunavir-based microbicides incorporating tenofovir may result in drug-drug interactions likely to affect distribution of individual drugs to sub-epithelial target cells.Conclusions These findings will help optimise complex formulations of rectal microbicides to realise their full potential as an effective approach for pre-exposure prophylaxis against HIV-1 infection.",
author = "Indrani Mukhopadhya and Murray, {Graeme I.} and Susan Berry and John Thomson and Bruce Frank and Garry Gwozdz and Julia Ekeruche-Makinde and Robin Shattock and Charles Kelly and Francesco Iannelli and Gianni Pozzi and El-Omar, {Emad M.} and Hold, {Georgina L.} and Karolin Hijazi",
note = "Funding This work was supported by the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement No 305316 as part of the MOTIF (Microbicide Optimization Through Innovative Formulation for Vaginal and Rectal Delivery) project. Acknowledgements We thank members of the MOTIF consortium for useful discussions and exchange of ideas during the course of this study. We would like to extend our thanks to the study participants and the clinical teams for their invaluable contribution. We thank NHS Grampian Biorepository for support in performing the immunohistochemical studies, Janssen R&D Ireland for provision of darunavir and Gilead Sciences for provision of tenofovir.",
year = "2016",
month = "2",
doi = "10.1093/jac/dkv335",
language = "English",
volume = "71",
pages = "372--386",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Drug Transporter Gene Expression in Human Colorectal Tissue and Cell Lines

T2 - Modulation with Antiretrovirals for Microbicide Optimization

AU - Mukhopadhya, Indrani

AU - Murray, Graeme I.

AU - Berry, Susan

AU - Thomson, John

AU - Frank, Bruce

AU - Gwozdz, Garry

AU - Ekeruche-Makinde, Julia

AU - Shattock, Robin

AU - Kelly, Charles

AU - Iannelli, Francesco

AU - Pozzi, Gianni

AU - El-Omar, Emad M.

AU - Hold, Georgina L.

AU - Hijazi, Karolin

N1 - Funding This work was supported by the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement No 305316 as part of the MOTIF (Microbicide Optimization Through Innovative Formulation for Vaginal and Rectal Delivery) project. Acknowledgements We thank members of the MOTIF consortium for useful discussions and exchange of ideas during the course of this study. We would like to extend our thanks to the study participants and the clinical teams for their invaluable contribution. We thank NHS Grampian Biorepository for support in performing the immunohistochemical studies, Janssen R&D Ireland for provision of darunavir and Gilead Sciences for provision of tenofovir.

PY - 2016/2

Y1 - 2016/2

N2 - Objectives To comprehensively assess mRNA expression of 84 drug transporters in human colorectal biopsies and 6 representative cell lines. To investigate the alteration of drug transporter gene expression after exposure to three candidate microbicidal ARV drugs, (tenofovir, darunavir and dapivirine) in Caco-2 cells. The outcome of the objectives informs development of optimal antiretroviral (ARV)-based microbicidal formulations for prevention of HIV-1 infection.Methods Drug transporter mRNA expression was quantified from colorectal biopsies and cell-lines by quantitative real-time PCR. Relative mRNA expression was quantified in Caco-2 cells after induction with ARVs. Data was analysed using Pearson’s correlation coefficients (r), hierarchical clustering and principal component analysis (PCA).Results Expression of 58 of the 84 transporters was documented in colorectal biopsies, with CNT2, P-gp and MRP3 being the highest expressed. No difference was noted between individual subjects, when analysed by age, gender or biopsy site (rectum or recto-sigmoid) (r=0.95-0.99). High expression of P-gp and CNT2 proteins was confirmed by immunohistochemical staining. Similarity between colorectal tissue and cell-line drug transporter gene expression was variable (r = 0.64-0.84). PCA showed distinct clustering of human colorectal biopsy samples with the Caco-2 cells defined as the best surrogate system. Induction of Caco-2 cell-lines with ARV drugs suggests that darunavir-based microbicides incorporating tenofovir may result in drug-drug interactions likely to affect distribution of individual drugs to sub-epithelial target cells.Conclusions These findings will help optimise complex formulations of rectal microbicides to realise their full potential as an effective approach for pre-exposure prophylaxis against HIV-1 infection.

AB - Objectives To comprehensively assess mRNA expression of 84 drug transporters in human colorectal biopsies and 6 representative cell lines. To investigate the alteration of drug transporter gene expression after exposure to three candidate microbicidal ARV drugs, (tenofovir, darunavir and dapivirine) in Caco-2 cells. The outcome of the objectives informs development of optimal antiretroviral (ARV)-based microbicidal formulations for prevention of HIV-1 infection.Methods Drug transporter mRNA expression was quantified from colorectal biopsies and cell-lines by quantitative real-time PCR. Relative mRNA expression was quantified in Caco-2 cells after induction with ARVs. Data was analysed using Pearson’s correlation coefficients (r), hierarchical clustering and principal component analysis (PCA).Results Expression of 58 of the 84 transporters was documented in colorectal biopsies, with CNT2, P-gp and MRP3 being the highest expressed. No difference was noted between individual subjects, when analysed by age, gender or biopsy site (rectum or recto-sigmoid) (r=0.95-0.99). High expression of P-gp and CNT2 proteins was confirmed by immunohistochemical staining. Similarity between colorectal tissue and cell-line drug transporter gene expression was variable (r = 0.64-0.84). PCA showed distinct clustering of human colorectal biopsy samples with the Caco-2 cells defined as the best surrogate system. Induction of Caco-2 cell-lines with ARV drugs suggests that darunavir-based microbicides incorporating tenofovir may result in drug-drug interactions likely to affect distribution of individual drugs to sub-epithelial target cells.Conclusions These findings will help optimise complex formulations of rectal microbicides to realise their full potential as an effective approach for pre-exposure prophylaxis against HIV-1 infection.

U2 - 10.1093/jac/dkv335

DO - 10.1093/jac/dkv335

M3 - Article

VL - 71

SP - 372

EP - 386

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 2

ER -